These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 12083844)

  • 1. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.
    Skiadopoulos MH; Surman SR; Riggs JM; Orvell C; Collins PL; Murphy BR
    Virology; 2002 May; 297(1):136-52. PubMed ID: 12083844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes.
    Skiadopoulos MH; Surman SR; Durbin AP; Collins PL; Murphy BR
    Virology; 2000 Jun; 272(1):225-34. PubMed ID: 10873765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.
    Durbin AP; Skiadopoulos MH; McAuliffe JM; Riggs JM; Surman SR; Collins PL; Murphy BR
    J Virol; 2000 Aug; 74(15):6821-31. PubMed ID: 10888621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.
    Liang B; Munir S; Amaro-Carambot E; Surman S; Mackow N; Yang L; Buchholz UJ; Collins PL; Schaap-Nutt A
    J Virol; 2014 Apr; 88(8):4237-50. PubMed ID: 24478424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates.
    Bukreyev A; Huang Z; Yang L; Elankumaran S; St Claire M; Murphy BR; Samal SK; Collins PL
    J Virol; 2005 Nov; 79(21):13275-84. PubMed ID: 16227250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic.
    Skiadopoulos MH; Schmidt AC; Riggs JM; Surman SR; Elkins WR; St Claire M; Collins PL; Murphy BR
    J Virol; 2003 Jan; 77(2):1141-8. PubMed ID: 12502830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys.
    Skiadopoulos MH; Surman SR; Riggs JM; Collins PL; Murphy BR
    J Virol; 2001 Nov; 75(21):10498-504. PubMed ID: 11581420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human parainfluenza virus 3 vaccine candidates attenuated by codon-pair deoptimization are immunogenic and protective in hamsters.
    Afroz S; Saul S; Dai J; Surman S; Liu X; Park HS; Le Nouën C; Lingemann M; Dahal B; Coleman JR; Mueller S; Collins PL; Buchholz UJ; Munir S
    Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2316376121. PubMed ID: 38861603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
    Tao T; Skiadopoulos MH; Davoodi F; Riggs JM; Collins PL; Murphy BR
    J Virol; 2000 Jul; 74(14):6448-58. PubMed ID: 10864657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The aberrant gene-end transcription signal of the matrix M gene of human parainfluenza virus type 3 downregulates fusion F protein expression and the F-specific antibody response in vivo.
    Lingemann M; Surman S; Amaro-Carambot E; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Mar; 89(6):3318-31. PubMed ID: 25589643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.
    Skiadopoulos MH; Tatem JM; Surman SR; Mitcho Y; Wu SL; Elkins WR; Murphy BR
    Vaccine; 2002 Mar; 20(13-14):1846-52. PubMed ID: 11906774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.
    Tao T; Durbin AP; Whitehead SS; Davoodi F; Collins PL; Murphy BR
    J Virol; 1998 Apr; 72(4):2955-61. PubMed ID: 9525616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine.
    Kobayashi H; Iwatsuki-Horimoto K; Kiso M; Uraki R; Ichiko Y; Takimoto T; Kawaoka Y
    Vaccine; 2013 Dec; 31(52):6239-46. PubMed ID: 24144478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Function and immunogenicity of human parainfluenza virus 3 glycoproteins expressed by recombinant adenoviruses.
    Ebata SN; Prevec L; Graham FL; Dimock K
    Virus Res; 1992 Jun; 24(1):21-33. PubMed ID: 1320799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.
    Schmidt AC; McAuliffe JM; Huang A; Surman SR; Bailly JE; Elkins WR; Collins PL; Murphy BR; Skiadopoulos MH
    J Virol; 2000 Oct; 74(19):8922-9. PubMed ID: 10982335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.